

MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom
gov.uk/mhra

Dr P Bath
UNIVERSITY OF NOTTINGHAM
D FLOOR, SOUTH BLOCK,
QUEENS MEDICAL CENTRE, DERBY ROAD
NOTTINGHAM
NG7 2UH
UNITED KINGDOM

08/07/2021

Dear Dr P Bath

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	CTA 03057/0073/001-0002
Eudract Number:	2021-000185-15
Product:	Ciclesonide, Niclosamide Ethanolamine
Protocol Number:	21001
Substantial Amendment Code Number:	Substantial Amendment 01

ACKNOWLEDGEMENT OF AMENDMENT

Thank you for your notice of amendment, received on 07/07/2021. The information you provided to support your request is complete and therefore your request is valid.

Your request will be assessed and you will be notified of the Licensing Authority's decision within 35 days.

Please quote the EudraCT number, CTA number and your amendment code in any further communications relating to this submission.

Yours sincerely,

Submissions
MHRA